HOLX Quote, Financials, Valuation and Earnings

Nuwellis has a net margin of -1.73% compared to Hologic's net margin of -63.22%. Hologic's return on equity of 11.45% beat Nuwellis's return on equity of -800.59%.

Hologic has a consensus price target of $68.10, signalling upside risk potential of 19.22%. On the other hand Nuwellis has an analysts' consensus of $13.00 which suggests that it could grow by 1213.13%. Given that Nuwellis has higher upside potential than Hologic, analysts believe Nuwellis is more attractive than Hologic.

Hologic has a beta of 0.544, which suggesting that the stock is 45.552% less volatile than S&P 500. In comparison Nuwellis has a beta of 0.505, suggesting its less volatile than the S&P 500 by 49.478%.

Hologic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nuwellis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hologic pays -- of its earnings as a dividend. Nuwellis pays out -- of its earnings as a dividend.

Hologic quarterly revenues are $1B, which are larger than Nuwellis quarterly revenues of $2.3M. Hologic's net income of -$17.4M is lower than Nuwellis's net income of -$1.5M. Notably, Hologic's price-to-earnings ratio is 24.10x while Nuwellis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hologic is 3.30x versus 0.18x for Nuwellis. Usually stocks with elevated PS ratios are considered overvalued.

Quanterix has a net margin of -1.73% compared to Hologic's net margin of -34.09%. Hologic's return on equity of 11.45% beat Quanterix's return on equity of -11.35%.

Hologic has a consensus price target of $68.10, signalling upside risk potential of 19.22%. On the other hand Quanterix has an analysts' consensus of $11.25 which suggests that it could grow by 111.61%. Given that Quanterix has higher upside potential than Hologic, analysts believe Quanterix is more attractive than Hologic.

Hologic has a beta of 0.544, which suggesting that the stock is 45.552% less volatile than S&P 500. In comparison Quanterix has a beta of 1.116, suggesting its more volatile than the S&P 500 by 11.641%.

Hologic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quanterix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hologic pays -- of its earnings as a dividend. Quanterix pays out -- of its earnings as a dividend.

Hologic quarterly revenues are $1B, which are larger than Quanterix quarterly revenues of $34.1M. Hologic's net income of -$17.4M is lower than Quanterix's net income of -$11.6M. Notably, Hologic's price-to-earnings ratio is 24.10x while Quanterix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hologic is 3.30x versus 1.62x for Quanterix. Usually stocks with elevated PS ratios are considered overvalued.

Steris PLC has a net margin of -1.73% compared to Hologic's net margin of 12.66%. Hologic's return on equity of 11.45% beat Steris PLC's return on equity of 7.27%.

Hologic has a consensus price target of $68.10, signalling upside risk potential of 19.22%. On the other hand Steris PLC has an analysts' consensus of $251.36 which suggests that it could grow by 7.83%. Given that Hologic has higher upside potential than Steris PLC, analysts believe Hologic is more attractive than Steris PLC.

Hologic has a beta of 0.544, which suggesting that the stock is 45.552% less volatile than S&P 500. In comparison Steris PLC has a beta of 0.956, suggesting its less volatile than the S&P 500 by 4.397%.

Hologic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Steris PLC offers a yield of 0.96% to investors and pays a quarterly dividend of $0.57 per share. Hologic pays -- of its earnings as a dividend. Steris PLC pays out 53.03% of its earnings as a dividend. Steris PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Hologic quarterly revenues are $1B, which are smaller than Steris PLC quarterly revenues of $1.4B. Hologic's net income of -$17.4M is lower than Steris PLC's net income of $173.5M. Notably, Hologic's price-to-earnings ratio is 24.10x while Steris PLC's PE ratio is 49.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hologic is 3.30x versus 4.29x for Steris PLC. Usually stocks with elevated PS ratios are considered overvalued.

Varex Imaging has a net margin of -1.73% compared to Hologic's net margin of 3.24%. Hologic's return on equity of 11.45% beat Varex Imaging's return on equity of -7.36%.

Hologic has a consensus price target of $68.10, signalling upside risk potential of 19.22%. On the other hand Varex Imaging has an analysts' consensus of $17.40 which suggests that it could grow by 131.38%. Given that Varex Imaging has higher upside potential than Hologic, analysts believe Varex Imaging is more attractive than Hologic.

Hologic has a beta of 0.544, which suggesting that the stock is 45.552% less volatile than S&P 500. In comparison Varex Imaging has a beta of 0.617, suggesting its less volatile than the S&P 500 by 38.305%.

Hologic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Varex Imaging offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hologic pays -- of its earnings as a dividend. Varex Imaging pays out -- of its earnings as a dividend.

Hologic quarterly revenues are $1B, which are larger than Varex Imaging quarterly revenues of $212.9M. Hologic's net income of -$17.4M is lower than Varex Imaging's net income of $6.9M. Notably, Hologic's price-to-earnings ratio is 24.10x while Varex Imaging's PE ratio is 17.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hologic is 3.30x versus 0.40x for Varex Imaging. Usually stocks with elevated PS ratios are considered overvalued.